Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000417401 | SCV000195509 | benign | not specified | 2016-03-30 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000417401 | SCV000209409 | benign | not specified | 2016-04-06 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV000558793 | SCV000641891 | benign | Mowat-Wilson syndrome | 2025-01-14 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002316956 | SCV000851366 | uncertain significance | Inborn genetic diseases | 2016-12-02 | criteria provided, single submitter | clinical testing | The p.Q3H variant (also known as c.9G>C), located in coding exon 1 of the ZEB2 gene, results from a G to C substitution at nucleotide position 9. The glutamine at codon 3 is replaced by histidine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on data from ExAC, the C allele has an overall frequency of approximately 0.034% (36/105,942) total alleles studied (TCGA excluded). The highest observed frequency was 0.216% (17/7,854) of East Asian alleles. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV000558793 | SCV002045617 | benign | Mowat-Wilson syndrome | 2021-11-07 | criteria provided, single submitter | clinical testing |